Ipilimumab in treatment-naive and previously treated patients with metastatic melanoma: Retrospective analysis of efficacy and safety data from a phase II trial

Journal of Immunotherapy

Volumn 35, Issue 1, 2012, Pages 73-77

  Thompson, John A ^a   Hamid, Omid ^b   Minor, David ^c   Amin, Asim ^d   Ron, Ilan G ^e   Ridolfi, Ruggero ^f   Assi, Hazem ^g   Berman, David ^h   Siegel, Jonathan ^h   Weber, Jeffrey S ⁱ  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Angeles Clinic and Research Institute   (United States)

^c CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^d CAROLINAS MEDICAL CENTER   (United States)

^e TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^f DEPARTMENT OF MEDICAL ONCOLOGY   (Italy)

^g MONCTON HOSPITAL   (Canada)

^h BRISTOL MYERS SQUIBB   (United States)

ⁱ H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

budesonide; CTLA 4; immunotherapy; metastatic melanoma; phase II trial

Indexed keywords

BUDESONIDE; IPILIMUMAB; PLACEBO;

ARTICLE; CANCER IMMUNOTHERAPY; COLITIS; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; HUMAN; MAJOR CLINICAL STUDY; MELANOMA; METASTASIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROPHYLAXIS; SURVIVAL RATE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BUDESONIDE; CTLA-4 ANTIGEN; DIARRHEA; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MELANOMA; NEOPLASM METASTASIS; NEOPLASM STAGING; RETROSPECTIVE STUDIES; SKIN NEOPLASMS; SURVIVAL ANALYSIS;

EID: 84155163012     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/CJI.0b013e31823735d6     Document Type: Article

References (22)

1. Manola J, Atkins M, Ibrahim J, et al. Prognostic factors in metastatic melanoma: a pooled analysis of Eastern Cooperative Oncology Group trials. J Clin Oncol. 2000;18:3782-3793.
2. Bedikian AY, Johnson MM, Warneke CL, et al. Prognostic factors that determine the long-term survival of patients with unresectable metastatic melanoma. Cancer Invest. 2008;26: 624-633.
3. Korn EL, Liu PY, Lee SJ, et al. Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol. 2008;26:527-534.
4. Tarhini AA, Agarwala SS. Cutaneous melanoma: available therapy for metastatic disease. Dermatol Ther. 2006;19:19-25.
5. Agarwala SS. Current systemic therapy for metastatic melanoma. Expert Rev Anticancer Ther. 2009;9:587-595.
6. Tsao H, Atkins MB, Sober AJ. Management of cutaneous melanoma. N Engl J Med. 2004;351:998-1012.
7. Fong L, Small EJ. Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment. J Clin Oncol. 2008;26: 5275-5283.
8. Weber J. Ipilimumab: controversies in its development, utility and autoimmune adverse events. Cancer Immunol Immunother. 2009;58:823-830.
9. Melero I, Hervas-Stubbs S, Glennie M, et al. Immunostimu-latory monoclonal antibodies for cancer therapy. Nat Rev Cancer. 2007;7:95-106.
10. Wolchok JD, Saenger Y. The mechanism of anti-CTLA-4 activity and the negative regulation of T-cell activation. Oncologist. 2008;13(suppl 4):2-9.
11. Weber J. Overcoming immunologic tolerance to melanoma: targeting CTLA-4 with ipilimumab (MDX-010). Oncologist. 2008;13(suppl 4):16-25.
12. Hoos A, Ibrahim R, Korman A, et al. Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy. Semin Oncol. 2010;37:533-546.
13. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711-723.
14. Downey SG, Klapper JA, Smith FO, et al. Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res. 2007;13:6681-6688.
15. Weber J, Thompson JA, Hamid O, et al. A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res. 2009;15:5591-5598
16. ClinicalTrials.gov. A companion study for patients enrolled in prior/parent ipilimumab studies. Available at http://clinical trials.gov/ct2/show/NCT00162123.
17. Petrella T, Quirt I, Verma S, et al. Melanoma Disease Site Group of Cancer Care Ontario's Program in Evidence-based Care. Single-agent interleukin-2 in the treatment of metastatic melanoma: a systematic review. Cancer Treat Rev. 2007;33:484-496.
18. Eggermont AM. Reaching first base in the treatment of metastatic melanoma. J Clin Oncol. 2006;24:4673-4674
19. National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology-Melanoma, v.3.2011. Available at http://www.nccn.org.
20. Ribas A, Hauschild A, Kefford R, et al. Phase III, open-label, randomized, comparative study of tremelimumab (CP-675,206) and chemotherapy (temozolomide [TMZ] or dacarbazine [DTIC]) in patients with advanced melanoma. J Clin Oncol. 2008;26(15s): abstract LBA9011.
21. Hauschild A, Agarwala SS, Trefzer U, et al. Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol. 2009;27:2823-2830.
22. Flaherty KT, Lee SJ, Schuchter LM, et al. Final results of E2603: a double-blind, randomized, phase III trial comparing carboplatin (C)/paclitaxel (P) with or without sorafenib (S) in metastatic melanoma. J Clin Oncol. 2009;28(15s): abstract 8511.